Personalized Solriamfetol Therapy Systems for Impaired Renal Function

The inventive concept integrates solriamfetol therapy with advanced technologies such as AI, IoT, blockchain, and novel materials to provide personalized treatment plans for subjects with impaired renal function, optimizing dosing regimens and minimizing adverse effects.

The original patent provides an optimized dose escalation scheme for subjects with moderate renal impairment, but it has limitations in terms of personalized treatment and real-time monitoring. The new inventive concept addresses these limitations by incorporating advanced technologies to provide more effective and efficient treatment plans.

The inventive concept comprises a system for personalized solriamfetol therapy, integrating a blockchain-based data management platform for storing and analyzing patient data, an AI-powered dosing algorithm for generating optimized dose escalation schemes, and a user interface for real-time monitoring and adjustment of therapy. Additionally, the system can be integrated with wearable IoT devices for monitoring renal function and adjusting dosing in real-time. The system can also utilize machine learning models to predict optimal solriamfetol dosing regimens and provide visualizations for healthcare providers. Furthermore, the inventive concept includes novel pharmaceutical compositions comprising solriamfetol and biodegradable materials for controlled release, optimizing bioavailability and minimizing adverse effects.

The new claims introduce novel combinations of solriamfetol therapy with advanced technologies, such as AI, IoT, blockchain, and novel materials, which are not obvious from the original patent. The integration of these technologies provides a new and non-obvious approach to personalized treatment plans for subjects with impaired renal function.

Alternative embodiments of the inventive concept could include the use of different AI algorithms or machine learning models, integration with different types of wearable devices or sensors, or the development of new biodegradable materials for controlled release of solriamfetol. Additionally, the system could be adapted for use in different therapeutic areas or for treatment of other medical conditions.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and digital health. The system could be marketed as a comprehensive solution for healthcare providers and patients, offering improved treatment outcomes and reduced healthcare costs.